New Mountain acquires Mallinckrodt Baker
An affiliate of New Mountain Capital announced the completion of its acquisition of Mallinckrodt Baker from Covidien for approximately $280 million.
An affiliate of New Mountain Capital announced the completion of its acquisition of Mallinckrodt Baker from Covidien for approximately $280 million.
Headquartered in New Jersey, Mallinckrodt Baker manufactures and markets high-purity chemicals and related services and products under brand names, J.T.Baker and Mallinckrodt Laboratory Chemicals. According to the company these products are widely used in research and quality control laboratories, microelectronics, environmental testing laboratories and universities, and for manufacturing in the pharmaceutical, biotechnology and other industrial markets. The company’s operations will continue as usual, with no supply interruptions or process changes anticipated as a result of the sale.
“We look forward to working with the Mallinckrodt Baker leadership to determine a strategic direction that promotes accelerated growth,” said Raj Gupta, former chairman and CEO of Rohm and Haas and a senior advisor at New Mountain, who will serve as the company’s chairman of the board. “With New Mountain as its partner, Mallinckrodt Baker will be positioned as a leading player in the speciality chemicals and materials industry.”
This story originally appeared in The Column. Click here to view that issue.
Understanding FDA Recommendations for N-Nitrosamine Impurity Levels
April 17th 2025We spoke with Josh Hoerner, general manager of Purisys, which specializes in a small volume custom synthesis and specialized controlled substance manufacturing, to gain his perspective on FDA’s recommendations for acceptable intake limits for N-nitrosamine impurities.
